All
FDA Grants Opdivo Priority Review for Small Cell Lung Cancer
April 19th 2018The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.
Frontline Opdivo-Yervoy Combo Shows Promise in Advanced Non-Small Cell Lung Cancer
April 17th 2018Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).
I'll Never Get to Ring the Bell
April 14th 2018Patients with cancer are often asked when they’ll be done with chemotherapy or treatment. Those of us with blood cancers and bone marrow type of cancers such as aplastic anemia, myelodysplastic syndrome, lymphoma and leukemia, along with a host of other cancers sadly have to say, “never.”
New Guidelines Aim to Improve Quality of Life For Patients With Advanced Lung Cancer
April 12th 2018Some patients with incurable non-small cell lung cancer (NSCLC) should receive chemotherapy concurrent with palliative thoracic radiation therapy, according to an updated guideline released by the American Society for Radiation Oncology (ASTRO).